Ogenix Corporation Announces Intent to License EpiFLO SD(R) Technology to Minerva Healthcare

Published: May 18, 2007

CLEVELAND & SAN FRANCISCO--(BUSINESS WIRE)--Ogenix Corporation today announced that it has agreed to grant an option to license its Transdermal Sustained Oxygen Therapy (TSOT) technology for wound healing and the treatment of skin disorders to Minerva Healthcare, Inc., for worldwide (except in Canada) distribution of its EpiFLO SDĀ® family of products.

Back to news